These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26256294)

  • 41. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials.
    Beyer WEP; Palache AM; Boulfich M; Osterhaus ADME
    Vaccine; 2017 Jul; 35(33):4167-4176. PubMed ID: 28655451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: Implications for vaccine composition strategy.
    Paiva TM; Benega MA; Silva DB; Santos KC; Cruz AS; Hortenci MF; Barbieri MT; Monteiro MM; Barbosa HA; Carvalhanas TR
    J Med Virol; 2013 Nov; 85(11):1983-9. PubMed ID: 23926069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    de Boer PT; Kelso JK; Halder N; Nguyen TP; Moyes J; Cohen C; Barr IG; Postma MJ; Milne GJ
    Vaccine; 2018 Feb; 36(7):997-1007. PubMed ID: 29373192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico.
    Ruiz-Palacios GM; Beigel JH; Guerrero ML; Bellier L; Tamayo R; Cervantes P; Alvarez FP; Galindo-Fraga A; Aguilar-Ituarte F; Lopez JG
    Hum Vaccin Immunother; 2020 Apr; 16(4):827-835. PubMed ID: 31851570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL; Levin MJ; Block SL; Belshe RB; Ambrose CS; Falloon J
    Expert Rev Vaccines; 2012 Nov; 11(11):1293-303. PubMed ID: 23151111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type.
    McLean HQ; Thompson MG; Sundaram ME; Kieke BA; Gaglani M; Murthy K; Piedra PA; Zimmerman RK; Nowalk MP; Raviotta JM; Jackson ML; Jackson L; Ohmit SE; Petrie JG; Monto AS; Meece JK; Thaker SN; Clippard JR; Spencer SM; Fry AM; Belongia EA
    J Infect Dis; 2015 May; 211(10):1529-40. PubMed ID: 25406334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden.
    Tisa V; Barberis I; Faccio V; Paganino C; Trucchi C; Martini M; Ansaldi F
    J Prev Med Hyg; 2016; 57(1):E28-33. PubMed ID: 27346937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inactivated influenza virus vaccines: the future of TIV and QIV.
    Schotsaert M; García-Sastre A
    Curr Opin Virol; 2017 Apr; 23():102-106. PubMed ID: 28505524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The need for quadrivalent vaccine against seasonal influenza.
    Belshe RB
    Vaccine; 2010 Sep; 28 Suppl 4():D45-53. PubMed ID: 20713260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
    Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
    Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The coming era of quadrivalent human influenza vaccines: who will benefit?
    Barr IG; Jelley LL
    Drugs; 2012 Dec; 72(17):2177-85. PubMed ID: 23110610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
    Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usage of quadrivalent influenza vaccine among children in the United States, 2013-14.
    Rodgers L; Pabst LJ; Zhu L; Chaves SS
    Vaccine; 2015 Nov; 33(48):6517-8. PubMed ID: 26296494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.
    Skowronski DM; Masaro C; Kwindt TL; Mak A; Petric M; Li Y; Sebastian R; Chong M; Tam T; De Serres G
    Vaccine; 2007 Apr; 25(15):2842-51. PubMed ID: 17081662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Omer I; Rosenberg A; Sefty H; Pando R; Mandelboim M; Mendelson E; Keinan-Boker L; Glatman-Freedman A;
    Vaccine; 2022 Feb; 40(6):880-885. PubMed ID: 35016804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The economic value of a quadrivalent versus trivalent influenza vaccine.
    Lee BY; Bartsch SM; Willig AM
    Vaccine; 2012 Dec; 30(52):7443-6. PubMed ID: 23084849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.